CM Life Sciences, Inc. CMLF
Set alert
11.60 0.00 0.00%
At close
11.40 Day range 12.43
9.66 52-week range 27.18
- Open
- 12.30
- Prev close
- 11.60
- Mkt cap
- 641.99M
- Vol
- 489.11K
- Avg vol
- 723.14K
- EPS
- -0.009
- P/E
- -1288.89
- Div yield
- 0.00%
More statistics
- Low
- 11.40
- High
- 12.43
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 2.64
- Inst. own
- 62.58%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 12.71
- 200-d avg
- 14.38
- 1y target
- 0.00
Key statistics
- Market cap
- 641.99M
- Enterprise value
- 641.82M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 128.89
- EPS (TTM)
- -0.009
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 167.96K
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 44.27M
- Short % of float
- 5.23%
- 50-day average
- 12.71
- 200-day average
- 14.38
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
About CM Life Sciences, Inc.
CM Life Sciences, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company focuses on targeting life science companies. CM Life Sciences, Inc. was incorporated in 2020 and is based in New York, New York.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
- Website
- i.cmlifesciencesspac.com
News
- CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business Combination
- 3 Stocks Cathie Wood Keeps Buying
- Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement
- Cathie Wood's ARK Invest Buys Over 330,000 Shares of CM Life Sciences
- Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger
- CM Life Sciences Announces Filing of Amended Annual Report on Form 10-K Relating to Restatement of Financial Statements in Accordance with Recent SEC Guidance
- CM Life Sciences II: SomaLogic Is Great, But Post-Merger SPAC Dilution Should Frighten Investors
- CM Life Sciences: SPAC Acquires Sema4, A Promising AI Health Intelligence Co.
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of CM Life Sciences, Inc. - CMLF
- CMLF Stock Price Increases Over 80% Over The Past Week: Why It Happened
Your note
Sign in to keep a note on CMLF — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 9.56% | 4,231,546 | 63.01M | Mar 30, 2021 |
| SB Management Ltd | 7.63% | 3,379,704 | 50.32M | Mar 30, 2021 |
| Weiss Multi-Strategy Advisers, LLC | 5.87% | 2,597,776 | 38.68M | Mar 30, 2021 |
| Alkeon Capital Management LLC | 5.22% | 2,310,000 | 34.40M | Mar 30, 2021 |
| Marshall Wace LLP | 4.60% | 2,038,507 | 30.35M | Mar 30, 2021 |
| Sachem Head Capital Management, LP | 3.39% | 1,500,000 | 22.34M | Mar 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Genomic Revolution ETF | 10.30% | 4,560,227 | 63.89M | Jun 29, 2021 |
| ACAP Strategic Fund | 2.41% | 1,067,890 | 15.90M | Mar 30, 2021 |
| Weiss Strategic Interval Fd | 1.19% | 527,448 | 7.85M | Mar 30, 2021 |
| Brinker Capital Destinations Tr-Destinations Multi Strategy Alt Fd | 1.15% | 510,787 | 10.22M | Feb 27, 2021 |
| Columbia Fds Ser Tr I-Columbia Small Cap Growth Fd I | 0.78% | 344,284 | 6.89M | Feb 27, 2021 |
| Advantage Advisers Xanthus Fund, LLC | 0.76% | 335,323 | 4.99M | Mar 30, 2021 |